Poly(l-glutamic acid)–anticancer drug conjugates

Add time:09/08/2019    Source:sciencedirect.com

Chemotherapy has had limited success in the treatment of cancer over the years, due, in part, to the untoward toxicity of the therapeutic agent to normal cells. The design of tailor-made polymer conjugates provides a synthetic approach that can overcome some of the problems. Several synthetic polymer-based anticancer drug conjugates have entered clinical studies. This report reviews the chemistry, physicochemical properties, and therapeutic applications in cancer therapy of polymeric chemotherapeutic agents based on poly(l-glutamic acid). Targeted delivery of anticancer agents using poly(l-glutamic acid) as the drug carrier is also discussed with emphasis on the design of innovative polymeric constructs.

We also recommend Trading Suppliers and Manufacturers of L-Glutamic acid alpha-benzyl ester (cas 13030-09-6). Pls Click Website Link as below: cas 13030-09-6 suppliers

Prev:FTIR evidence for antiparallel β-sheet structures of long oligomeric N-acetyl-l-glutamic acid benzyl esters
Next:pH-dependent self-assembly of amphiphilic poly(l-glutamic acid)-block-poly(lactic-co-glycolic acid) copolymers)